232 results about "Live virus" patented technology

The invention discloses a bovine rotavirus monoclonal antibody and a preparation method of a bovine rotavirus quantum dot immunochromatography test strip, and belongs to the technical field of bovine rotavirus monoclonal antibodies. According to the invention, a hybridoma cell strain BRV 3G9 is utilized, and a monoclonal antibody is prepared by adopting an ascites method; the BRV 3G9 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.46138. The BRV 3G9 is named as BRV 3G9. According to the present invention, the concentrated live virus immunized mouse is adopted to prepare the monoclonal antibody with strong immunoreaction, and the BRV quantum dot immunochromatography test strip is researched and developed on the basis of the monoclonal antibody, and has advantages of convenient use, high efficiency, high sensitivity, strong specificity and the like, and can achieve the rapid clinical differential diagnosis of calf diarrhea pathogens, the problem that grassroots veterinarians lack a clinical rapid detection technology is solved, the diagnosis and treatment level and the prevention and treatment effect are improved, and technical guarantee is provided for efficiently preventing and treating calf diarrhea and guaranteeing calf health.

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention provides a method for detecting a virus inactivation effect by an ELISA (Enzyme-Linked Immunosorbent Assay) method, which comprises the following steps: acquiring a to-be-detected inactivated virus sample, extracting an antigen component from the sample, and detecting an antigen structure change characteristic value through a high-throughput mass spectrometry analysis technology to obtain antigen degradation degree data; obtaining a sample subjected to preliminary inactivation, and detecting the antigen content change trend through an enzyme-linked immunosorbent assay to obtain content change curve data; detecting the residual quantity of viral nucleic acid by a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) technology aiming at the immunogenicity retained sample to obtain nucleic acid degradation degree data; acquiring nucleic acid degradation degree data, classifying the relationship between nucleic acid residues and infectivity by adopting a support vector machine algorithm, and judging that the inactivation effect is completely completed if the classification result shows that the infectivity is lost; according to the antigen content change trend, the immunogenicity index and the nucleic acid degradation degree data, a weighted fusion algorithm is adopted to integrate multi-dimensional detection results, and a comprehensive inactivation effect score is obtained.

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

A fermentation enhancement device for use in a bioreactor, the fermentation enhancement device comprising: an electrical charge structure defining an inner volume arranged for accommodating a fermentation process, the electrical charge structure comprising: a piezoelectric proliferation layer exposed to the inner volume; and a piezoelectric virucidal layer arranged at an outer surface of the electrical charge structure; an opening configured to allow therethrough a flow of nutrients and / or bacteria; wherein the fermentation enhancement device is arranged such that actuation of the electrical charge structure, by an actuation source, generates an electrical charge at the virucidal layer that kills and / or inactivates viruses, and an electrical charge at the proliferation layer that stimulates bacterial growth.

The present invention provides a method for inactivating viruses in liquid biological products. The method uses a virus inactivation device to inactivate viruses in liquid biological products. The virus inactivation device includes a feeding part, a centrifugation part, and a discharging part. The centrifugation part is provided with an ultraviolet lamp. The liquid biological products are continuously fed into the centrifugation part through the feeding part. Under the action of centrifugation, the liquid biological products are thinned to a liquid layer thickness of 0.01 cm to 0.2 cm, and at the same time, the viruses are inactivated by ultraviolet irradiation through the ultraviolet lamp. After the viruses are inactivated, the liquid biological products are continuously discharged from the centrifugation part to the discharging part under the action of centrifugation, and are discharged from the virus inactivation device through the discharging part. The retention time of the liquid biological products in the centrifugation part is controlled to be 5 to 60 s, the irradiation intensity of the ultraviolet lamp is 500 to 10,000 μW / cm<supgt;2< / supgt;, and the irradiation wavelength of the ultraviolet lamp is 254 to 280 nm. The present invention is a continuous method for inactivating viruses in liquid biological products.

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.

The invention belongs to the technical field of veterinary medicine, and provides a co-expressed recombinant porcine alpha and gamma interferon. The I-type interferon alpha and the II-type interferon gamma not only exert the anti-virus, anti-cell division and immune regulation effects of the interferon, but also can activate T cells and natural killer cells, and fully exert the multiple activities of the interferon. The two interferons are co-expressed in insect cells, the expression protein can be folded and then processed and modified, the structure of the expression protein is closer to a natural structure, the biological activity is high, the recombinant protein is easy to purify, the production scale is easy to expand, and live viruses or potential dangerous pathogens do not need to be treated, so that the production cost is reduced; by optimizing the production process and fermentation conditions, the quality and stability of the recombinant protein can be further improved.

The invention discloses a lactobacillus fermentum strain as well as extracellular vesicles and application thereof. The lactobacillus fermentum strain is named as C283, is preserved in the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, and has the microbial preservation number of CGMCC No.30338. The lactobacillus fermentum strain can be used for preparing the lactobacillus fermentum. Researches show that the strain has unique anti-inflammatory and anti-infection dual characteristics, and also has the characteristics of acid resistance, cholate resistance and the like; particularly, the C283 strain can generate extracellular vesicles with very strong immunologic adjuvant activity and immunological enhancement activity, and the C283 strain outer vesicles can directly activate chicken mucous membrane epithelium lymphocytes only through nasal dripping and eye dripping, so that mucous membrane immune response is remarkably enhanced; particularly, the strain exovesicle can be directly used as an efficient mucosal delivery carrier for inactivated viruses or antigens, nucleic acid vaccines or mRNA vaccines, and efficient mucosal immune system delivery of the inactivated vaccines or antigens can be achieved in a mucosal immune mode. The invention provides a new technical means for preparing novel oral vaccines and mucous membrane delivery vaccines.

The invention discloses a veterinary vaccine composite adjuvant as well as a preparation method and application thereof. Active ingredients in the vaccine composite adjuvant are a manganese-containing compound and a Mincle agonist. According to the veterinary vaccine composite adjuvant disclosed by the invention, Mn and TDB are combined, so that the immunological enhancement effect of the TDB adjuvant is achieved. The composite adjuvant can induce a strong immune response reaction, significantly improves the immune effect, and is free of residual damage in use. Compared with the H7N9 vaccine prepared by singly using DDA-TDB, the H7N9 vaccine prepared by mixing the H7N9 subtype avian influenza inactivated virus as the antigen with the composite adjuvant can enhance humoral immunity and cellular immune response of a body, reduce virus load and improve protection level, and provides a product and technical support for production of veterinary vaccines.

The invention relates to a polypeptide Nb3-26 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-26 is constructed; meanwhile, the curative effect of the Nb3-26 on treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

The invention discloses a poliomyelitis vaccine and a preparation method thereof. A vaccine prepared from the poliomyelitis virus-like particles is used for inoculation immunization, high-level neutralizing antibodies aiming at poliomyelitis I type, poliomyelitis II type and poliomyelitis III type can be generated, and the poliomyelitis virus-like particles have broad-spectrum neutralizing activity on current extensive epidemic strains. The recombinant poliomyelitis vaccine does not depend on live viruses, no live viruses and no biological safety risk exist in the vaccine production and verification process, the situation that derived cases of OPV vaccines are generated cannot be caused, meanwhile, the requirement for high-level facilities needed by IPV vaccine production and verification does not exist, the production and quality control cost is reduced, and the production cost and the quality control cost of the recombinant poliomyelitis vaccine are improved. The vaccine accessibility of middle and low income countries can be improved.

The invention discloses an avian flavivirus NS1 trans-complementary pseudovirus system and application thereof. According to the pseudovirus system disclosed by the invention, a BHK21 cell line for stably expressing USUV-NS1 protein carrying a V5 label, namely a BHK21-NS1 stably transfected cell line, is constructed by utilizing a lentivirus packaging method; meanwhile, deletion mutation is introduced into the NS1 protein of USUV, infectious clone plasmids are constructed, and the 157th-251st amino acid of the NS1 protein is deleted by the deletion mutation. The infectious clone plasmid is transfected with a BHK21-NS1 stably transfected cell line, so that the trans-complementary virus USUV-delta NS1 which can be rescued and proliferated only in the BHK21-NS1 stably transfected cell line is obtained. The USUV-deltaNS1 trans-complementary virus is subjected to continuous passage on a BHK21-NS1 cell for 10 generations, so that the TMN-deltaNS1 virus with high yield is obtained, and complete live virus is not generated by recombination in the passage process. Therefore, the avian flavivirus NS1 trans-complementary pseudovirus system disclosed by the invention can be used as a tool to be applied to USUV vaccine preparation and related antibody evaluation.

The invention relates to a VHH nano antibody Nb3-17 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-17 is constructed; meanwhile, the curative effect of Nb3-17 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention relates to a multi-antigen monkey pox RNA vaccine and a preparation method thereof, and relates to the technical field of nucleic acid vaccines. The multi-antigen mRNA comprises a sequence encoding an antigenic polypeptide of the monkey pox virus or an antigenic fragment, variant or derivative thereof, the antigenic polypeptide or the antigenic fragment thereof comprising at least viral proteins of an intracellular mature virus and an extracellular envelope virus of the monkey pox virus. The invention provides a multi-antigen mRNA vaccine aiming at monkey pox viruses and a sequence, mRNA can express antigen protein in in-vitro cells, high-titer anti-monkey pox virus A29L, A33L, B6R, M1R and E8L protein IgG can be detected after a mouse is immunized, a high-titer anti-vaccinia Tian Tan strain live virus neutralizing antibody is generated, good immunogenicity is achieved, and the vaccine can be used for preparing the multi-antigen mRNA vaccine aiming at the monkey pox viruses. The important significance is realized on the prevention of the monkey pox virus.

Provided are a viral or bacterial inactivation agent composition and a method for inactivating a virus or a bacterium that have high inactivation effects on viruses and bacteria even under the condition of using a quaternary ammonium salt-type surfactant at a low concentration. A viral or bacterial inactivation agent composition containing, (A) a quaternary ammonium salt-type surfactant, (B) an aliphatic alcohol with 8 or more and 24 or less carbons having a branched alkyl group or a linear alkenyl group and water.

A nucleic acid construct encoding multiple polypeptide antigens or immunogens or other polypeptides of interest. The construct expresses a protein that comprises immunogenic or antigenic sequences of two, three or more polypeptides of interest. Once expressed by the nucleic acid construct, the protein, is processed by cleavage of an N-terminal signal peptide and cleavage of 6K, 6K-like, or internal signal peptide cleavage sites to release each polypeptide of interest. Vectors, including replicons and live virus vectors, comprising the construct may be used to deliver it to a subject in need of vaccination. Vaccines and methods of treatment using the nucleic acid construct are also described.

Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

The invention discloses a porcine pseudorabies virus strain, a construction method of a reverse genetic manipulation platform of the porcine pseudorabies virus strain, a recombinant porcine pseudorabies virus and application of the recombinant porcine pseudorabies virus, the porcine pseudorabies virus strain is a porcine pseudorabies virus PRV-HL-2021 strain, the preservation number of the porcine pseudorabies virus strain is CGMCC No.46094, and the porcine pseudorabies virus strain is preserved in China General Microbiological Culture Collection Center on July 29, 2024. The invention provides a porcine pseudorabies virus strain, and constructs a college reverse genetic manipulation platform for the porcine pseudorabies virus strain, so that the porcine pseudorabies virus gene can be quickly and accurately modified, the function of the porcine pseudorabies virus gene can be researched, and a new live virus vector is developed for the research of recombinant vaccines.

Viral inactivation apparatus and method for the inactivation of live virus species. A fluid flow bioreactor is provided having an elongate flow channel adapted to control fluid flow characteristics of a solution containing suspended viral particles for irradiation by a suitable radiation source to produce inactive viral species suitable for vaccine synthesis. The present bioreactor configuration is advantageous to control administration of irradiation dosage to reliably and efficiently create inactivated viral species at 100% effectiveness whilst preserving structural integrity of the viral species so as to provide an effective inactivated vaccine.

Certain embodiments of the invention provide compositions and methods for nucleic acid delivery by engineered virus-like nanocarriers in plant cells. Certain embodiments of the invention provide a nanoparticle, comprising a cationic polymer (e.g., poly-(allylamine) or salt thereof) conjugated to the nanoparticle, wherein the nanoparticle is a live virus (e.g., TMGMV), or an inactivated virus (e.g., iTMGMV).

The invention relates to the technical field of preparation of veterinary antiviral traditional Chinese medicines, in particular to application of naringenin in preparation of an anti-EHV-8 medicine, including application of a naringenin monomer, a plant extract containing the naringenin monomer and a traditional Chinese medicine compound in preparation of an EHV-8 replication inhibiting medicine. The naringenin disclosed by the invention plays an antiviral role in an EHV-8 replication stage, cannot directly inactivate viruses, has the maximum safe concentration of 100 mu M, has a remarkable inhibition effect on a plurality of strains, can reduce lung injury of a mouse model caused by EHV-8 infection, is natural in source and low in toxicity, has various pharmacological activities such as anti-inflammation and the like, and provides a reference for anti-EHV-8 clinical medication.

The invention discloses a PDCoV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The amino acid sequence of the PDCoV-S1 recombinant protein antigen disclosed by the invention is as shown in SEQ ID NO: 1; the nucleotide sequence of the PDCoV-S1 recombinant protein antigen is as shown in SEQ ID NO: 2. The vaccine provided by the invention only contains recombinant PDCoV-S1 protein and does not contain genetic materials of viruses, so that all risks of virus replication, virulence reversion or gene recombination are fundamentally avoided. Live viruses do not need to be operated in the production process, so that the biological safety risk and the requirement on the production environment are greatly reduced. The constructed stable CHO engineering cell strain is combined with a serum-free suspension culture technology, so that high-density, large-scale and standardized production of the PDCoV-S1 protein can be realized in a bioreactor. The production process is stable and reliable, the batch-to-batch consistency is good, and the uncertainty and volatility caused by the virus culture link of the traditional vaccine are overcome.

This invention relates to the field of plant extract application technology, particularly to banana fruit extract and its applications. This invention reveals that banana fruit extract exhibits excellent performance in relieving inflammation, anti-oxidation, scavenging free radicals, delaying cell aging, inhibiting viruses and bacteria (inactivating HPV, Staphylococcus aureus, Candida albicans, Escherichia coli, and Propionibacterium acnes), reducing infection, promoting cell regeneration and repair, promoting collagen synthesis, enhancing elasticity and firmness, and acting as a plant-derived immunomodulator. Furthermore, it serves as a natural, intelligent transdermal carrier. Safe and non-irritating, this extraction method has shown excellent application value in high-value plants such as saffron, rose, Dendrobium officinale, ginseng, and Ganoderma lucidum. It provides a comprehensive solution for skin from defense to regeneration, offering a regulatory-compliant natural solution for functional skincare.

The present invention relates to a computer-implemented method for determining the need to add a mitigating agent to feed to inactivate viruses that may be present in the feed. A preferred mitigating agent is a mixture comprising benzoic acid tablets and a powder comprising eugenol and thymol. The mixture rapidly inactivates viruses even when added only in low concentrations. This is particularly applicable to (but not limited to) porcine epidemic diarrhea virus (PEDV). Thus, by the present invention, the animal feed is substantially free of harmful viral RNA.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.